BRPI0708071A8 - Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos - Google Patents

Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos

Info

Publication number
BRPI0708071A8
BRPI0708071A8 BRPI0708071A BRPI0708071A BRPI0708071A8 BR PI0708071 A8 BRPI0708071 A8 BR PI0708071A8 BR PI0708071 A BRPI0708071 A BR PI0708071A BR PI0708071 A BRPI0708071 A BR PI0708071A BR PI0708071 A8 BRPI0708071 A8 BR PI0708071A8
Authority
BR
Brazil
Prior art keywords
compounds
catecholamine derivatives
deuterated catecholamine
drugs including
well
Prior art date
Application number
BRPI0708071A
Other languages
English (en)
Inventor
Alken Rudolf-Giesbert
Schneider Frank
Original Assignee
Birds Pharma Gmbh Berolina Innovative Res & Development Services
Imphar Ag
Ratiopharm Gmbh
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Birds Pharma Gmbh Berolina Innovative Res & Development Services, Imphar Ag, Ratiopharm Gmbh, Teva Pharmaceuticals Int Gmbh filed Critical Birds Pharma Gmbh Berolina Innovative Res & Development Services
Publication of BRPI0708071A2 publication Critical patent/BRPI0708071A2/pt
Publication of BRPI0708071A8 publication Critical patent/BRPI0708071A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

DERIVADOS DE CATECOLAMINA DEUTERADA E MEDICAMENTOS COMPREENDENDO OS DITOS COMPOSTOS. A presente invenção refere-se a derivados de catecolamina deuterada, assim como a medicamentos contendo esses compostos. Em adição, a presente invenção refere-se ao uso de derivados de catecolamina deuterada, assim como os sais fisiologicamente aceitáveis dos mesmos, e também a composições farmacêuticas, que contêm estes compostos, também em combinação com inibidores de enzima, para o tratamento de doenças por deficiência de dopamina ou de doenças que se baseiem em transporte de tirosina interrompido ou tirosina descarboxilase interrompida, assim como de outros distúrbios.
BRPI0708071A 2006-02-17 2007-02-16 Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos BRPI0708071A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006008316.4 2006-02-17
DE102006008316 2006-02-17
PCT/EP2007/001555 WO2007093450A2 (en) 2006-02-17 2007-02-16 Deuterated catecholamine derivatives and medicaments comprising said compounds

Publications (2)

Publication Number Publication Date
BRPI0708071A2 BRPI0708071A2 (pt) 2011-05-17
BRPI0708071A8 true BRPI0708071A8 (pt) 2017-12-26

Family

ID=38236462

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0708071A BRPI0708071A8 (pt) 2006-02-17 2007-02-16 Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos

Country Status (24)

Country Link
US (2) USRE46555E1 (pt)
EP (2) EP1991522B1 (pt)
JP (1) JP5248331B2 (pt)
KR (1) KR101411422B1 (pt)
CN (1) CN101384545B (pt)
AU (1) AU2007214622B2 (pt)
BR (1) BRPI0708071A8 (pt)
CA (1) CA2642593C (pt)
CY (1) CY1117995T1 (pt)
DK (1) DK1991522T3 (pt)
EA (1) EA017983B1 (pt)
ES (1) ES2587368T3 (pt)
HR (1) HRP20161039T1 (pt)
HU (1) HUE028777T2 (pt)
IL (1) IL193102A (pt)
LT (1) LT1991522T (pt)
ME (1) ME02508B (pt)
PL (1) PL1991522T3 (pt)
PT (1) PT1991522T (pt)
RS (1) RS55142B1 (pt)
SI (1) SI1991522T1 (pt)
UA (1) UA97795C2 (pt)
WO (1) WO2007093450A2 (pt)
ZA (1) ZA200806568B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
PL2303330T5 (pl) 2008-06-06 2021-10-25 Pharma Two B Ltd. Kompozycje farmaceutyczne do leczenia choroby Parkinsona
BRPI0916769A2 (pt) 2008-07-15 2017-09-26 Theracos Inc derivados de benzilbenzeno deuterados e métodos de uso
WO2013127831A1 (en) 2012-02-28 2013-09-06 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
US9763904B2 (en) 2013-02-05 2017-09-19 Teva Pharmaceuticals International Gmbh Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds
BR112015016889A8 (pt) * 2013-02-05 2018-01-23 Imphar Ag derivados de catecolamina enriquecidos com deutério em posição específica
WO2014174425A2 (en) * 2013-04-24 2014-10-30 Mahesh Kandula Compositions and methods for the treatment of orthostasis and neurological diseases
PE20160556A1 (es) * 2013-07-08 2016-06-11 Auspex Pharmaceuticals Inc Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos
JP2017503756A (ja) * 2013-11-22 2017-02-02 オースペックス ファーマシューティカルズ インコーポレイテッド 異常な筋活動を処置する方法
MX369956B (es) 2013-12-03 2019-11-27 Auspex Pharmaceuticals Inc Metodos para preparar compuestos de benzoquinolina.
WO2015120110A2 (en) 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
EP2918266A1 (en) 2014-03-11 2015-09-16 CDRD Berolina AB Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
GB201420341D0 (en) * 2014-11-17 2014-12-31 Evolution Valves Ltd Valve arrangement
MX2017011459A (es) 2015-03-06 2018-04-24 Auspex Pharmaceuticals Inc Metodos para el tratamiento de trastornos del movimiento involuntario anormal.
CN106343013A (zh) * 2015-07-19 2017-01-25 中国科学院上海有机化学研究所 一种粮食储存方法
AR106313A1 (es) 2015-10-09 2018-01-03 Teva Pharmaceuticals Int Gmbh Combinación de levodopa deuterada con carbidopa y opicapona para el tratamiento de enfermedad de parkinson
CN105360267B (zh) * 2015-10-09 2017-11-10 青岛振坤食品机械有限公司 一种全自动穿串机
CN105862897B (zh) * 2016-04-11 2018-01-16 江苏省华建建设股份有限公司 砂质泥岩地基浅基础原槽浇筑施工工法
AU2019392924A1 (en) * 2018-12-06 2021-06-17 Senda Biosciences, Inc Quaternary ammonium salts as inhibitors of trimethylamine production

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3699158A (en) 1969-08-25 1972-10-17 Merck & Co Inc Selective deuteration of tyrosine, aspartic and glutamic acids
DE2049807A1 (en) 1970-10-10 1972-04-13 Hartmeyer H Conversion of closed cell plastics foam to - open cell structure
DE2049115C3 (de) 1970-10-06 1981-07-30 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, Tokyo Verwendung von Calcium-5-butylpicolinat und/oder Calcium-5-pentylpicolinat bei der Bekämpfung des Parkinsonismus mit 3-(3,4-Dihydroxyphenyl)-L-alanin (L-Dopa)
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
IT1226902B (it) 1988-07-12 1991-02-21 Mini Ricerca Scient Tecnolog Processo per la sintesi del levodopa
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
DE10261808A1 (de) 2002-12-19 2004-07-08 Turicum Drug Development Ag Verwendung von L-DOPA, seiner Derivate und diese Verbindungen enthaltender Arzneimittel zur Prophylaxe psychotischer Erkrankungen
DE10261807A1 (de) 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel

Also Published As

Publication number Publication date
EP1991522B1 (en) 2016-05-18
ME02508B (me) 2017-06-20
HRP20161039T1 (hr) 2016-11-04
HUE028777T2 (en) 2017-01-30
EA017983B1 (ru) 2013-04-30
CN101384545A (zh) 2009-03-11
BRPI0708071A2 (pt) 2011-05-17
EP3101001A1 (en) 2016-12-07
RS55142B1 (sr) 2016-12-30
JP5248331B2 (ja) 2013-07-31
US20090018191A1 (en) 2009-01-15
WO2007093450A3 (en) 2007-09-27
CN101384545B (zh) 2014-09-03
PT1991522T (pt) 2016-08-23
JP2009526799A (ja) 2009-07-23
AU2007214622A1 (en) 2007-08-23
USRE46555E1 (en) 2017-09-19
CA2642593C (en) 2014-11-04
EP1991522A2 (en) 2008-11-19
CY1117995T1 (el) 2017-05-17
IL193102A (en) 2015-01-29
ES2587368T3 (es) 2016-10-24
EA200801826A1 (ru) 2009-02-27
WO2007093450A2 (en) 2007-08-23
LT1991522T (lt) 2016-09-26
KR20080106539A (ko) 2008-12-08
DK1991522T3 (en) 2016-08-29
IL193102A0 (en) 2009-02-11
ZA200806568B (en) 2009-07-29
AU2007214622B2 (en) 2012-02-23
KR101411422B1 (ko) 2014-07-03
SI1991522T1 (sl) 2016-10-28
EP3101001B1 (en) 2020-04-01
CA2642593A1 (en) 2007-08-23
UA97795C2 (uk) 2012-03-26
PL1991522T3 (pl) 2017-07-31
US8247603B2 (en) 2012-08-21

Similar Documents

Publication Publication Date Title
BRPI0708071A8 (pt) Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
BRPI0916668A2 (pt) composições e métodos para anticorpos direcionados à proteína do complemento c5
BR112015007083A2 (pt) inibidores de histona demetilases
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
GT200600028A (es) Compuestos y composiciones como inhibidores de proteina kinasa
BR112012009376A2 (pt) composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso
GT200900057A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
BRPI0519351A2 (pt) medicamentos para o tratamento ou prevenÇço de doenÇas fibràticas
HK1142062A1 (en) Oxadiazole derivatives active on sphingosine-1-phosphate (s1p)
BRPI0906444B8 (pt) compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BRPI0706992C8 (pt) composto de fórmula (i) e formulação farmacêutica
BR112012005044A2 (pt) composições que compreendem tramadol e celecoxib no tratamento de dor.
BR112012006010A2 (pt) composto de glicina
BRPI0513857A (pt) inibidores de hsp90
BR112012015202A2 (pt) "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes".
BR112012017884A2 (pt) composto, composição farmacêutica, uso de um composto, derivado de pirazina, métodos para o tratamento ou prevenção, para promoção óssea, e, para tratar lesões ósseas em cânceres
HK1086548A1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
BR112012022074A2 (pt) composição compreendendo como ingredientes ativos l-carnitina em combinação com hidroxiquinurenina-o-beta-dl-glicosídeo, para a prevenção e/ou tratamento de patologias dos olhos devido à radiação ultravioleta
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: BIRDS PHARMA GMBH BEROLINA INNOVATIVE RESEARCH AND

B25A Requested transfer of rights approved

Owner name: IMPHAR AKTIENGESELLSCHAFT (DE)

B25A Requested transfer of rights approved

Owner name: RATIOPHARM GMBH (DE)

B25A Requested transfer of rights approved

Owner name: TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements